Kings Research today released its latest market intelligence report titled “Global Nasal Cannula Market: Size, Share, Trends & Forecast 2024–2031.” The report offers a rigorous assessment of the nasal cannula landscape, delving into segments by size, prongs, type, and geography, while profiling competitive dynamics and adoption forces.
Per Kings Research’s internal modeling, the global nasal cannula market is estimated at USD 8,230.0 million in 2023. It is projected to grow to USD 8,676.2 million in 2024 and further to USD 13,245.1 million by 2031, corresponding to a compound annual growth rate (CAGR) of 6.23% over the forecast period.
Clinical studies also show that high-flow oxygen therapy can reduce intubation rates and speed recovery in respiratory illness. For example, one trial found that among patients receiving high-flow oxygen, the intubation rate was 34.3%, versus 51.0% in those on conventional oxygen therapy (hazard ratio 0.62) over 28 days (Source: https://www.cidrap.umn.edu/). These clinical benefits strengthen the case for growing adoption of advanced nasal cannula systems.
A nasal cannula is a medical device used to deliver supplemental oxygen or increased airflow via two prongs inserted into the nostrils. It is widely used in hospitals, ambulatory, and home settings due to its minimal invasiveness. Conventional (low-flow) nasal cannulas typically deliver oxygen at small flow rates (1–5 L/min). Beyond that threshold, discomfort, nasal dryness, or mucosal irritation may occur. High-flow nasal cannula (HFNC) systems, however, deliver heated and humidified oxygen (up to 60 L/min) with precise FiO₂ control.
Because respiratory illnesses are rising globally, and healthcare models are shifting toward outpatient and home-based care, nasal cannulas remain a cornerstone for oxygen therapy in both acute and chronic care contexts.
Kings Research identifies five principal growth accelerators:
- Growing Burden of Chronic Respiratory Diseases
Diseases such as chronic obstructive pulmonary disease (COPD), asthma, and pneumonia continue to rise globally. Epidemiological reviews (e.g., from IHME) show increases in prevalence and mortality of chronic respiratory conditions over recent decades. These underlying disease trends fuel demand for long-term and acute oxygen support devices. Despite impacting over 380 million people worldwide, chronic obstructive pulmonary disease (COPD) silently ends over 3 million lives every year. (Source: https://www.who.int/)
- Shift to Home Oxygen & Ambulatory Care
Many patients are now managed outside the hospital setting, under home oxygen therapy. Government records suggest more than one million Medicare recipients receive home LTOT at a cost exceeding $2 billion per year in the United States (Source: https://pmc.ncbi.nlm.nih.gov/). As home oxygen penetration grows, demand for comfortable, durable nasal cannulas rises.
- Public Health Preparedness & Stockpiling
In response to respiratory disease surges (e.g., during COVID-19), governments have procured HFNC kits as part of strategic reserves. For instance, the U.S. ASPR procured 30,000 HFNC kits for the Strategic National Stockpile to support surge capacity. (Source: https://www.aha.org/)
For executives in medical devices, respiratory care, hospital systems, and home care providers, the nasal cannula market offers strong strategic opportunities:
- Reliable, Recurring Demand: Oxygen therapy is a necessity in many chronic and acute cases, creating sustained demand for cannulas.
- Differentiation via Comfort & Performance: Advanced designs (HFNC compatibility, soft materials) can become competitive differentiators.
- Scalable Manufacturing & Cost Leverage: High volumes, streamlined materials (e.g., silicone, plastic), and economies of scale support margin expansion.
- Access Expansion: Firms can gain share by serving home care and emerging markets where oxygen therapy adoption is rising.
- Regulatory & Clinical Endorsement: Clinical studies showing lower intubation or improved outcomes can support product adoption and reimbursement positioning.
Regional Outlook
- North America: North America leads in clinical adoption of advanced respiratory therapies and home oxygen coverage.
- Asia-Pacific: APAC is poised to be the fastest-growing region, supported by rising healthcare investments, increasing respiratory disease burden, and expanding home care infrastructure.
Competitive Landscape
Key players shaping the nasal cannula market space include Hamilton Medical, ResMed, TNI Medical AG, Teleflex Incorporated, Vapotherm, Flexicare (Group) Limited, Fairmont Medical, Fisher & Paykel Healthcare Limited., Fleming Medical Ltd, and Medline Industries, LP. These companies are actively innovating, licensing, and scaling interfaces, materials, and distribution networks to maintain leadership.
The full Kings Research report includes detailed segmentation by size, prongs, type (low-flow vs high-flow), and geography, plus subregional forecasts, competitor profiling, SWOTs, and adoption pathways. To request a sample, download the full report, or explore bespoke consulting services, please visit https://www.kingsresearch.com/nasal-cannula-market-871.
About Kings Research
Kings Research is a global market intelligence and consulting firm specializing in medical devices, life sciences, and healthcare innovation. We empower decision-makers—corporates, investors, and governments—with evidence-based insights grounded in public data and domain expertise.
All data in this press release are based on Kings Research’s proprietary modeling, cross-validated against publicly available research, government sources, and industry publications. Key external references include the Center for Infectious Disease Research & Policy, the American Hospital Association, the National Institutes of Health (NIH), and the World Health Organization (WHO).